One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Conclusions The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women.
PMID: 23531117 [PubMed - as supplied by publisher] (Source: Climacteric)
Source: Climacteric - May 11, 2013 Category: Geriatrics Authors: Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K Tags: Climacteric Source Type: research
Drospirenone and non‐fatal venous thromboembolism: Is there a risk difference by dosage of Ethinyl‐Estradiol?
ConclusionsWe observed modestly elevated VTE risk with drospirenone, compared to levonorgestrel. The larger VTE incidence‐rate observed in DRSP/EE20 than DRSP/EE30, and the increasing VTE incidence‐rate with levonorgestrel between 2007‐2009 were unexpected.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - April 11, 2013 Category: Hematology Authors: Steven T Bird, Joseph A C Delaney, Mahyar Etminan, James M Brophy, Abraham G Hartzema Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Hormonal contraceptives and venous thromboembolism: An epidemiological update
In conclusion, newer generation formulations of hormonal contraceptives, as well as the non-oral hormonal contraceptive, seem to be more thrombogenic than second generation hormonal contraceptives. (Source: Best Practice and Research. Clinical Endocrinology and Metabolism)
Source: Best Practice and Research. Clinical Endocrinology and Metabolism - February 1, 2013 Category: Endocrinology Authors: Genevieve Plu-Bureau, Lorraine Maitrot-Mantelet, Justine Hugon-Rodin, Marianne Canonico Source Type: research
Drospirenone‐containing oral contraceptives and risk of adverse outcomes after myocardial infarction
Conclusion:This is the first study to evaluate the myocardial infarction risk and its subsequent clinical sequelae in women having a STEMI while taking the OC‐Yasmin. Women on the oral contraception Yasmin, who underwent coronary revascularization had a lower post‐procedural complete ST resolution and worse left ventricular function. Furthermore, OC use with Yasmin is an independent predictor of a high‐grade thrombus burden. © 2013 Wiley Periodicals, Inc. (Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - January 30, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Can Yucel Karabay, Gonenc Kocabay, Vecih Oduncu, Arzu Kalayci, Ahmet Guler, Ali Karagöz, Ozkan Candan, Ozcan Basaran, Regayip Zehir, Akın İzgi, Ali Metin Esen, Cevat Kırma Tags: Original Study Source Type: research
Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination
Conclusion: Lean women with PCOS have similar body composition compared to healthy women. OC therapy for 6 months in PCOS patients results in an increased total and trunk fat percentage despite no change in clinical anthropometric measures including weight, BMI and WHR. (Source: Contraception)
Source: Contraception - August 14, 2012 Category: OBGYN Authors: Kadriye Aydin, Nese Cinar, Duygu Yazgan Aksoy, Gurkan Bozdag, Bulent Okan Yildiz Tags: Original Research Articles Source Type: research
